{"entity":{"id":"adcendo","kind":"company","name":"Adcendo","aka":[],"tldr":"Adcendo is a Danish company developing antibody-drug conjugates, antibodies that deliver a cell-killing drug straight to cancer cells, against targets few others are pursuing. Its first medicines are in early human trials, including one for soft tissue sarcoma.","summary":"Adcendo ApS is a clinical-stage Copenhagen biotech developing antibody-drug conjugates against targets, such as tissue factor and uPARAP, that few other companies pursue. Its pipeline comprises ADCE-T02, a tissue factor-targeted ADC in the phase 1 Tiffany-01 study (cohort expansion in multiple solid tumour indications from April 2026, with a pembrolizumab combination cohort agreed with MSD in May 2026); ADCE-D01, a uPARAP-targeted ADC in the ADCElerate1 dose escalation and expansion study in soft tissue sarcoma and other mesenchymal cancers; and ADCE-B05, against an undisclosed target, in dose escalation in squamous cell carcinomas. The company closed an oversubscribed USD 135 million Series B in November 2024 led by TCGX, and a USD 75 million Series C in April 2026 led by Jeito Capital with Vida Ventures, Bpifrance and EIFO joining existing investors including RA Capital, Novo Holdings and Ysios Capital.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://adcendo.com/"},{"label":"Series B press release","url":"https://adcendo.com/adcendo-aps-completes-oversubscribed-135-million-series-b-financing-to-advance-first-in-class-adc-pipeline/"},{"label":"Series C press release","url":"https://adcendo.com/adcendo-aps-completes-75-million-series-c-financing-to-continue-advancing-first-and-best-in-class-clinical-adc-pipeline/"}],"tags":[],"related":[],"cancers":["sarcoma"],"sections":["adcs"],"technologies":["adc"],"targets":["tissue-factor"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06797999"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Earlier Series A (2021) not fetched and omitted. Founding year not stated on fetched pages."],"hq":"Copenhagen","country":"DK","companyType":"biotech","website":"https://adcendo.com/","stage":"growth","investors":["tcgx","orbimed","venrock","logos-capital","ra-capital","novo-holdings","gilde-healthcare","jeito-capital","vida-ventures","bpifrance"],"funding":[{"round":"Series B","year":2024,"amountUsd":135000000,"source":"https://adcendo.com/adcendo-aps-completes-oversubscribed-135-million-series-b-financing-to-advance-first-in-class-adc-pipeline/"},{"round":"Series C","year":2026,"amountUsd":75000000,"source":"https://adcendo.com/adcendo-aps-completes-75-million-series-c-financing-to-continue-advancing-first-and-best-in-class-clinical-adc-pipeline/"}]},"route":"/companies/adcendo/","neighbours":{"cancer":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"tissue-factor","kind":"target","name":"Tissue factor","route":"/targets/tissue-factor/"}],"trial":[{"id":"nct06797999","kind":"trial","name":"First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma","route":"/trials/nct06797999/"}],"company":[{"id":"bpifrance","kind":"company","name":"Bpifrance","route":"/companies/bpifrance/"},{"id":"gilde-healthcare","kind":"company","name":"Gilde Healthcare","route":"/companies/gilde-healthcare/"},{"id":"jeito-capital","kind":"company","name":"Jeito Capital","route":"/companies/jeito-capital/"},{"id":"logos-capital","kind":"company","name":"Logos Capital","route":"/companies/logos-capital/"},{"id":"novo-holdings","kind":"company","name":"Novo Holdings","route":"/companies/novo-holdings/"},{"id":"orbimed","kind":"company","name":"OrbiMed","route":"/companies/orbimed/"},{"id":"ra-capital","kind":"company","name":"RA Capital Management","route":"/companies/ra-capital/"},{"id":"tcgx","kind":"company","name":"TCGX (TCG Crossover)","route":"/companies/tcgx/"},{"id":"venrock","kind":"company","name":"Venrock","route":"/companies/venrock/"},{"id":"vida-ventures","kind":"company","name":"Vida Ventures","route":"/companies/vida-ventures/"}]}}